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 Abstract 
  Background:   Cell transplantation is a ‘hype and hope’ in the current scenario. It is in the early 
stage of development with promises to restore function in chronic diseases. Mesenchymal stem 
cell (MSC) transplantation in stroke patients has shown significant improvement by reducing 
clinical and functional deficits. They are feasible and multipotent and have homing character-
istics. This study evaluates the safety, feasibility and efficacy of autologous MSC transplantation 
in patients with chronic stroke using clinical scores and functional imaging (blood oxygen level-
dependent and diffusion tensor imaging techniques).  Methods:  Twelve chronic stroke patients 
were recruited; inclusion criteria were stroke lasting 3 months to 1 year, motor strength of hand 
muscles of at least 2, and NIHSS of 4–15, and patients had to be conscious and able to compre-
hend. Fugl Meyer (FM), modified Barthel index (mBI), MRC, Ashworth tone grade scale scores 
and functional imaging scans were assessed at baseline, and after 8 and 24 weeks. Bone mar-
row was aspirated under aseptic conditions and expansion of MSC took 3 weeks with animal 
serum-free media (Stem Pro SFM). Six patients were administered a mean of 50–60   !   10 6   cells 
i.v. followed by 8 weeks of physiotherapy. Six patients served as controls. This was a non-ran-
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domized experimental controlled trial.   Results:   Clinical and radiological scanning was normal 
for the stem cell group patients. There was no mortality or cell-related adverse reaction. The 
laboratory tests on days 1, 3, 5 and 7 were also normal in the MSC group till the last follow-up. 
The FM and mBI showed a modest increase in the stem cell group compared to controls. There 
was an increased number of cluster activation of Brodmann areas BA 4 and BA 6 after stem cell 
infusion compared to controls, indicating neural plasticity.   Conclusion:   MSC therapy aiming to 
restore function in stroke is safe and feasible. Further randomized controlled trials are needed 
to evaluate its efficacy.    Copyright © 2011 S. Karger AG, Basel 
 Introduction 
  Stroke is the leading cause of morbidity worldwide with a prevalence rate of approxi-
mately 250–300/100,000 in the total population   [1]   in Asian countries, and 28.5 million dis-
ability adjusted life years are estimated to be lost   [2]   due to stroke leaving 60% of stroke sur-
vivors dependent on caregivers for their daily activities. Urged by the expectation of func-
tional neuronal replacement, stem cell transplantation has emerged as a ‘hope’ to cure disease 
in the last decade. Several studies have evidenced a potential benefit of stem cell grafts in 
animal models and clinical trials of stroke  [3] . It is also postulated that stem cells operate not 
only through one unidirectional mechanism (e.g. generating neurons) but rather as cellular 
mediators of a multitude of biological activities that could provide a favorable outcome for 
neurogenic diseases   [4]  .
  Mesenchymal  Stem  Cells 
  Mesenchymal stem cells (MSC) are self-renewing, multipotent cells that can differenti-
ate into bone, cartilage, adipose tissues and neural precursors   [5–7]  . Intravenously adminis-
tered MSC have been shown to promote engraftment of hematopoietic lineages in cancers 
and ameliorate graft-versus-host disease   [8–10]  . The only published trial with a 5-year fol-
low-up of functional potential in stroke patients receiving autologous MSC transplantation 
reported significant improvement in the activities of daily living   [11]  . MSC possess immu-
nomodulatory properties, limit the local inflammatory response by decreasing activation of 
microglia and macrophages and impair T-lymphocyte maturation   [12]  .
    Recovery as Neural Plasticity 
  Initial recovery following an acute insult/stroke is mediated by spontaneous internal 
events, and after a late phase this recovery is remodeled by both external and internal per-
turbations   [13, 14]  . It has been suggested that 3 months is the time point recognized gener-
ally to get the functional status of a stroke victim  [15] . Functional neuroimaging investigates 
the biological mechanism of treatment effects in which blood oxygen level-dependent 
(BOLD) and diffusion tensor imaging (DTI) techniques are used to study the functionality 
and integrity of brain areas   [16, 17]  .
    Stem Cells as Regenerative Medicine 
  The emergence of stem cell biology has led to perennial applications in regenerative 
medicine for stroke aiming to restore plasticity for improving functional recovery  [18] . When 
introduced into the lesioned central nervous system, stem cells can have a positive influence 
through their intrinsic neuroprotective properties, e.g. production of growth and trophic 
factors, stimulation of endogenous neurogenesis and modulation of neuroinflammation. 
They are known to influence the environment by reorganizing the brain, and promoting 95
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learning in the form of synaptogenesis and dendritic sprouting   [19, 20]  . Transplanted stem 
cells also interact with the host tissue by forming connections and by providing ‘scaffolds’ to 
an injured brain in order to rescue dysfunctional and dormant cells   [21]  . 
    Cell therapies are setting new paradigms in regenerative medicine. This research evalu-
ates the safety, tolerance and possible efficacy of intravenous autologous MSC transplanta-
tion in chronic stroke assessed clinically and by functional imaging (BOLD and DTI).
  M e t h o d s  
  Patients diagnosed with stroke (index event) 3 months to 1 year ago, with MRC (Medi-
cal Research Council) grade of muscle power for the wrist and hand extensor or flexor mus-
cles of at least 2, and NIHSS (National Institute of Health Stroke Scale) between 4 and 15 who 
were conscious and able to comprehend were recruited for this study. We excluded patients 
with bleeding disorders, chronic liver and/or renal failure, progressive neurological worsen-
ing, unilateral neglect, neoplasia and with contraindications to MRI, and immunocompro-
mised and pregnant patients.
    The patients were divided into two groups matched for age, disease severity, time of 
stroke onset and lesion size. All the patients were examined by a neurologist and a neuro-
physiotherapist regarding muscle power (MRC), tone (modified Ashworth) and Fugl Meyer 
(FM) scale for upper limbs and modified Barthel index (mBI) at baseline, and the 8- and 24-
week follow-ups   [22]  . We used the Edinburgh handedness inventory to assess hand domi-
nance   [23]  . The detailed flow chart of the study is explained in   figure 1  . BOLD and DTI 
techniques were performed at baseline, and after 8 and 24 weeks of cell therapy. 
    The trial protocol and informed consent form were approved by the Institute Commit-
tee for Stem Cell Research and Therapy. A neurologist helped in treatment allocation but was 
not part of the study. Only the functional imaging parameters were blinded in this research.
  P r o c e d u r e s  
  Bone Marrow Aspiration, Expansion and Transplantation  . Bone marrow was aspirated 
under aseptic conditions from the posterior superior iliac crest of 6 chronic stroke patients. 
The aspirate was diluted with phosphate-buffered saline, layered over Ficoll density medium 
and centrifuged at 1,800 r.p.m. for 25 min. The collected mononuclear cell layer was plated at 
a density of 1   !   10 6   cells/cm 2   with Stem Pro MSC SFM basal medium (A-10334, Invitrogen) 
in a T-25 tissue culture flask and incubated at 37    °   C/5%  CO 2  . The cells were harvested and 
seeded at 3,000 or 10,000 cells/cm  2  in triplicate wells of 6-well plates. Throughout the duration 
of the culture, individual wells remained separate and were propagated individually. On reach-
ing 70–90% confluence, all MSC cultures were harvested using TrypLE  TM   Express (Invitro-
gen), counted flow cytometrically and reseeded at the same seeding density till the final re-
quired dose of cells was obtained. Nonadherent cells were removed after 24 h and fresh media 
were again added for incubation   [24, 25]  . The media were exchanged every 3 days and at con-
fluency, the cells were trypsinized and subcultured. All samples were tested for mycoplasma 
and endotoxins at every third passage using commercially available kits according to the man-
ufacturer’s instructions. MSC expansion took around 23   8   3 days. We used an aseptic infu-
sion technique. Cells were directly dissolved in a 250-ml saline bottle and infused intrave-
nously over 2–3 h using a sterile 50-ml syringe. We used a 20-gauge cannula for cell injection. 
Patients were evaluated for safety, i.e. laboratory tests (hemoglobin, red and white blood cells, 
platelets, liver and kidney function tests and partial thromboplastin time) 1, 3 and 7 days and 
24 weeks after transplantation. As the patients received an 8-week physiotherapy regime after 
cell transplantation, they were examined and evaluated daily for any adverse reaction. 96
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   Neuromotor Rehabilitation  . The physiotherapy regime administered to all 12 patients 
was based on the motor imagery   [26, 27]   incorporating learning and repetition of motor 
learning and lasted 60–90 min 5 days/week for 8 weeks. 
   fMRI Acquisition.  Subjects were asked to perform the motor task with the affected hand, 
with self-paced (minimum 0.5 Hz) fist clenching/extension of the wrist or metacarpopha-
langeal joint of the hand. BOLD data were acquired using the gradient echoplanar imaging 
sequence using a 1.5-tesla MR scanner (Avanto, Siemens, Germany). Block design with al-
ternate baseline and activation cycles was used with a total of 90 whole-brain echoplanar 
imaging measurements (TR = 4,520 ms, TE = 44 ms, slices = 31 and slice thickness = 4 mm) 
and MPrage sequence with 176 contiguous slices of 1.0-mm thickness   [28, 29]  .
   Diffusion Tensor Images.   They were acquired with single-shot echoplanar technique 
with b values of 0, 400 and 1,000 s/mm  2   in 20 directions, 128   !   128 matrix, field of view: 
230   !   230 mm, TE = 76 ms, TR = 10,726 ms, echoplanar imaging factor = 127 and a slice 
thickness of 2.3 mm. The termination criteria used were fractional anisotropy (FA)  ! 0.2 with 
an angle change   1  45°. Seed points as regions of interest (ROI) were drawn in the infarcted 
area and corticospinal tract in the affected and unaffected hemispheres   [30, 31]  . The selec-
tion of ROI for FA were repeated thrice by one rater, and the average value was regarded as 
the unit of measurement (intrarater reliability 0.88).
  S t a t i s t i c s    
  Statistical analysis was done by SPSS 11.5. We used parametric paired sample t test/
Kruskal-Wallis test for intragroup and 2-sample t test/Mann-Whitney test for intergroup 
comparisons with p = 0.05. Repeated-measure ANOVA was used to calculate the difference 
at baseline, and 8 and 24 weeks.
  Fig. 1.   Flow chart depicting the plan of the study. 97
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  R e s u l t s  
  Establishment of Safety
The routine laboratory tests 1, 3 and 7 days after the stem cell transplantation were nor-
mal for all patients. Flow-cytometric analysis showed phenotype markers which justify these 
cells as MSC or stromal cells. The cells expressed CD90, CD73 and CD105, and were nega-
tive for HLA class II. The mean CD90, CD73 and CD105 were 61, 57.1 and 40%, respectively. 
The mean cell viability at transplantation was 98% (performed with trypan blue stain); the 
cells were sterile and endotoxin free during expansion and at the time of injection. There 
were no early and late adverse reactions observed in patients during and after transplanta-
tion. The patients did not report any tumorigenesis, ectopic tissue formation or any behav-
ioral abnormality during the follow-up. 
  Clinical  Results 
  In the MSC or experimental group (males:females = 2:     4), all had right-hand dominance 
with age = 42   8   16.4 years (mean 8 SD); the mean FM score was 16.6   8   5.27 at baseline 
and 29   8   7.45 after 8 weeks. Patients showed statistically significant improvement when 
transplanted with stem cells (p = 0.001, t = –8.357). At the 24-week follow-up, the mean FM 
score was 36.6  8  7.4, which was higher than the mean at 8 weeks in these patients exhibiting 
statistically significant improvement (p = 0.001, t = –8.174). Repeated-measure ANOVA was 
found to be statistically significant at all time measurements, i.e. at baseline and after 8 and 
24 weeks. The mean mBI in the MSC group were 48.75   8   10.56 and 68.75   8   12.27 at base-
line and 8 weeks, respectively (p = 0.0001), and increased to 78.6   8   11.34 at 24 weeks (p   !  
0.05). In the control group (all males with right-hand dominance), mean age was 47.08  8  9.9 
years. The mean FM scores were 16.8   8   6.1 and 27.1   8   6.4 at baseline and 8 weeks, respec-
tively. These patients also showed statistically significant improvement between baseline and 
8 weeks after therapy, and between 8 and 24 weeks (p   !   0.05) for both FM and mBI scores 
( table 1 ). 
Table 1. D  emographic and clinical data in the MSC and the control group at baseline, and 8 and 24 weeks
No. Group Age,
years/
sex
Months
after
stroke 
Lesion area 
all MCA territory
Lesion
volume 
ml
CD90
%
CD73
%
CD105
%
Baseline 8 weeks 2  4 weeks
FM
n/66
mBI 
n/100
FM
n/66
mBI
n/100
FM
n /66
mBI
n/100
1 E 28/F 11 R frontoparietal (I) 12 40 40 44 22 52 36 72 44 80
2 E 20/F 12 R frontoparietal (H) 58 52 58 38 11 30 22 42 30 60
3 E 59/F 7 R frontal (I) 34.6 67 65 23 11 40 26 55 32 70
4 E 35/F 8 L internal capsule (H) 13.5 45 43 48 14 32 20 53 28 65
5 E 55/M 9 R frontal (I) 14.2 76 76 52 22 52 38 65 44 78
6 E 55/M 8 R frontal (I) 15.1 86 61 35 20 58 32 70 42 82
Mean 42 9.3 24.5 61 57.1 40 16.6 44 29 59.5 36.6 72.5
1 C 40/M 10 L frontal (I) 55 – – – 11 40 20 55 30 65
2 C 28/M 12 R parietal (I) 12.2 – – – 20 52 31 62 38 78
3 C 42/M 8 R internal capsule (I) 15.4 – – – 12 35 26 52 36 65
4 C 30/M 12 L temporoparietal (I) 45.5 – – – 11 42 20 50 30 68
5 C 60/M 7 L caudate (I) 10 – – – 24 55 36 65 33 73
6 C 50/M R frontoparietal (H) 11.2 – – – 23 50 30 68 38 72
Mean 46.5 9.3 24.8 – – – 16.8 45.6 27.1 58.6 34.1 70.1
C =   Control; E = MSC; R = right; L = left; I = ischemia; H = hemorrhage.98
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  BOLD  Activation  Pattern 
  The laterality index (LI) was calculated in each subject with a threshold of 10 voxels. It 
was measured with the formula LI = (CL – I)/(CL + I), where CL = the number of voxels of 
the contralateral hemisphere to the affected hand and I = the number of voxels for the ipsi-
lateral hemisphere to the affected hand. In the MSC group, the LI of the ipsilesional primary 
motor cortex (BA 4) did not show statistically significant improvement between 0 and 8 
weeks (p = 0.15) and between 8 and 24 weeks (p = 0.98;   table 2  ). The LI of the ipsilesional 
premotor motor cortex (BA 6) showed statistically significant improvement (p = 0.01) be-
tween 0 and 8 weeks but was not significant between 8 and 24 weeks (p  1  0.05). In the control 
group, the LI for the primary motor and premotor cortex (BA 4 and BA 6, respectively) was 
not statistically significant when calculated between 0 and 8 weeks and 8 and 24 weeks. 
    The FA ratio was calculated as FA of the affected hemisphere (ah) divided by the unaf-
fected hemisphere (uh). The FA  ah   was decreased compared to FA  uh   in both groups. We also 
calculated the fiber density by calculating the number of fibers (FN) and the fiber length (FL) 
in the given ROI in the affected and the unaffected hemispheres. We calculated the FL  ah /FL uh  
ratio, and the FN  ah /FN uh  ratio. In the MSC group, the mean FL  ah  (mm) were 0.12  8  0.05 mm 
at week 0, and 0.14   8   0.05 and 0.15   8   0.06 mm after 8 and 24 weeks, whereas in the control 
arm they were 0.09  8  0.03, 0.10  8  0.04 and 0.11  8  0.04 mm, respectively. There was no sig-
nificant change in FL in the MSC and control groups after 8 and 24 weeks. The mean fiber 
density (number) ratio (FN  ah /FN uh  ) in the MSC group was 0.28, 0.40 and 0.48 at baseline, 
and 8 and 24 weeks, and 0.25, 0.29 and 0.34, respectively, in the control group (nonsignifi-
cant: p   1   0.05). 
    Comparison between MSC and Control Groups 
  There was no significant difference in baseline clinical and radiological scores between 
the MSC and control groups, suggesting that the two groups were comparable to study the 
effectiveness of therapy after 8 and 24 weeks. There was no significant difference in FM and 
mBI scores after therapy (8 weeks: p = 0.87, t = 0.161 and p = 0.95, t = 0.065, respectively; 
  fig. 2  ) and at follow-up (p = 0.65 and p = 0.75, respectively;   fig. 3  ). A meager reduction in the 
Ashworth tone scale was observed between the two groups (  fig. 4  ).
  The LI of BA 4 and 6 between MSC and control groups was also statistically insignificant 
after 8 and 24 weeks (p   1   0.5). There was no statistically significant (p   1   0.05) change in the 
FA ratio, FL ratio and FN ratio between the two groups after 8 and 24 weeks. 
    We compared the results of right-hemispheric stroke with the control arm patients after 
8 weeks (  table 3  ). It was found that BA 4 and 6, and the inferior temporal gyrus (  fig. 5  ) of the 
affected hemisphere were active with a cluster count of 40 and 112 voxels, respectively. The 
results were similar at 24 weeks (cluster activation of 71 and 112 voxels of BA 4 and BA 6, 
respectively). 
  Discussion 
  This is the first known trial (to our knowledge) that establishes the safety and tolerance 
of MSC derived using serum-free media for expansion unlike bovine serum used in the ear-
lier study   [11, 12, 24, 25]  . We were able to procure 50–60 million cells at a mean of 4 pas-
sages in all the 6 patients, which made autologous MSC transplantation feasible. No immu-
nosuppressants were required following transplantation, eliminating the risks associated 
with MSC therapy. The clinical, laboratory and radiological evaluations did not report any 
deaths, cell-related complications, stroke recurrence and structural changes in imaging up 
to the 6-month follow-up. 99
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  Fig. 4.   Mean Ashworth scores between the MSC 
and control groups.  
  Fig. 5.   Comparison of BOLD activation between 
the MSC and control groups in right-hemispheric 
stroke overlaid on rendered images. 
  Fig. 2.   Mean FM scores at baseline, and at the 8- 
and 24-week follow-ups with p values in the MSC 
(stem cell) and control groups. 
  Fig. 3.   Mean mBI scores at baseline, and the 8- and 
24-week follow-ups with p values in the MSC (stem 
cell) and control groups. 101
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  The MSC group had 5 cortical and 1 subcortical lesions, 2 patients (patients 2 and 4) were 
hemorrhagic, and the remainder was ischemic with a lesion volume of 12–58 ml. All patients 
in this group showed significant improvement after 8 and 24 weeks versus baseline. The con-
trol patients had 4 cortical and 2 subcortical lesions (volume: 10–55 ml). All patients in this 
group showed significant improvement after 8 and 24 weeks versus baseline. Using the 2-sam-
ple t test, we observed no statistically significant (p   1   0.05) difference in FM, mBI, LI and FA 
ratios between both study groups after 8 and 24 weeks. However, the mean percentage change 
in FM scores between 8 weeks and baseline levels and between 8 and 24 weeks were 74.6 and 
26.2%, respectively, in the MSC group and 61.3 and 25.8% in the control arm, respectively. 
The change from baseline to the 24-week follow-up was 120% in the MSC group compared to 
102% in the control group, suggesting a minor trend to improvement in patients administered 
MSC. There was only a minor change in the power of wrist and hand muscles (subjective 
analysis) compared to the control group, though we observed a decrease in tone in spastic 
muscles, a lower pain threshold and a better functional performance in the MSC group ( fig. 4 ).
    In 1 MSC patient (No. 2) who had a large right temporoparietal lesion, we observed a 
shift in the LI from negative to positive (  table 3  ). At baseline, there was an increased activa-
tion in the supplementary motor cortex (BA 6) compared with the primary execution area 
(BA 4) in nearly all patients (recruitment principle of plasticity)   [32, 33]  . After an 8-week 
physiotherapeutic regime, there was an increased number of voxels in BA 6 in both groups. 
In the MSC group, the premotor and supplementary motor areas (BA 6) had an increased 
number of voxels active at the 24-week follow-up suggesting the ‘focusing’ principle of neu-
ral plasticity although the LI at the 24-week follow-up was not statistically significant (p   !  
0.05) between both groups. We noticed a considerable increase in LI and signal intensity  [34]  
from baseline to 8 weeks indicating that a focused exercise regime which involves vigorous 
training of the hand leads to increased force of activation performing better in the fMRI task 
compared to the performance at 24 weeks.
    We correlated FM scores with FA ratios at 24 weeks and found no significant difference 
in improvement between the MSC and the control group, but 4 of 6 patients (patients 1, 3, 5 
and 6) in the MSC group showed good recovery at follow-up with FA   1  0.6, whereas in the 
control group only 3 of 6 patients improved. This minute change in the integrity of the mo-
tor tract system might have been due to axonal remodeling imposed by the transplanted 
MSC   [35, 36]   although there was no statistical significant change in FL and FN ratios be-
tween the groups. 
Table 3. C  omparison of BOLD activation between the MSC and the control group at 24 weeks in right-
hemispheric stroke
Cluster z score MNI coordinates 
(x, y, z), mm
Hemisphere Area of activation Brodmann 
area
71 4.02 16, –,50, 54 right cerebrum precentral sulcus BA 4
112 2.95 18, –36, 46 right cerebrum medial frontal gyrus BA 6
56 4.05 –54, –36, 26 right cerebrum inferior parietal lobule BA 40
40 4.56 –48, 4, –8 left cerebrum superior temporal gyrus BA 22, 21
92 3.97 8, –40, 28 right cerebrum cingulate gyrus BA 31
95 3.36 –2, 18, 34 left cerebrum cingulate gyrus BA 32
87 2.99 –14, –12, 20 left cerebrum caudate caudate body
115 2.50 –48, –14, –26 left cerebrum inferior temporal gyrus BA 20, 21
O  ne cluster 2*2*2 mm3. MNI = Montreal Neurologic Institute. 102
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